Katia Scotlandi, PhD
Department of Experimental Oncology,
Othopedic Rizzoli Institute
40136-Bologna, Italy
Tel.: 39-051-6366 760
FAX: 39-051-6366 763
mailto:katia.scotlandi@ior.it

Present Position

• Chief of UO: Development of Biomolecular Therapies
• Professor of Molecular Biology - University of Bologna, Italy

Societies

• Board of Directors of the Italian Society of Cancer
  and of Italian Association for Cell Culture.
• Founder of Italian Sarcoma Group
  Member of:
  
• American Association for Cancer Research
• European Association for Cancr Research
• Connective Tissue Oncology Society
• Insulin-like growth factor Society

Research Themes

• Definition of targeted and differentiation therapies in sarcomas
• Matricellular proteins in the resistance and progression of tumors
• Cross-talk between IGF system and tumor microenvironment
• Gene expression profiling and miRNAs regulating mesenchymal stem cell differentiation

Selected Recent Publications

• Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL, Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J, Kovar H.
  Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
  Oncogene. 2011 Jan 10
• Meynet O, Scotlandi K, Pradelli E, Manara MC, Colombo MP, Schmid-Antomarchi H, Picci P, Bernard A, Bernard G.
  Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness.
  Cancer Res. 2010 May 1;70(9):3730-8.
• Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K.
  CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
  J Clin Invest. 2010 Mar 1;120(3):668-80.
• Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.
  NVP-BEZ235 as a new therapeutic option for sarcomas.
  Clin Cancer Res. 2010 Jan 15;16(2):530-40.
• Scotlandi K, Picci P, Kovar H.
  Targeted therapies in bone sarcomas.
  Curr Cancer Drug Targets. 2009 Nov;9(7):843-53. Review.
• Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P.
  Prognostic relevance of CCN3 in Ewing sarcoma.
  Hum Pathol. 2009 Oct;40(10):1479-86.
• Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, Lollini PL, Ferrari S, Alberghini M, Llombart-Bosch A, Piccolo E, Iacobelli S, Picci P, Scotlandi K.
  Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
  Int J Cancer. 2010 Jan 1;126(1):41-52.
• Serra M, Scotlandi K.
  Caveolins in the development and diseases of musculoskeletal system.
  Cancer Lett. 2009 Nov 1;284(2):113-21.
• Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, Francesconi M, Mercuri M, Caccuri AM, Serra M, Knuutila S, Picci P.
  Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
  J Clin Oncol. 2009 May 1;27(13):2209-16.
• Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K.
  Prognostic value of CCN3 in osteosarcoma.
  Clin Cancer Res. 2008 Feb 1;14(3):701-9.